Efficacy of sorafenib combined with transcatheter arterial chemoembolization in treatment of patients with middle and advanced hepatocellular carcinoma

  Objective  To observe the clinical efficacy of sorafenib combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with middle and advanced liver cancer.

  Methods  Totally 150 patients with middle and advanced liver cancer were divided into simple treatment group and combined intervention group. The efficacy, adverse reactions and 1-, 3-, 5-year survival rates were compared between the two groups. The expressions of serum glypican-3 (GPC3) and latent transforming growth factor beta binding protein 2 (LTBP2) were compared between the two groups before and after treatment.

  Results  Efficacy of the combined intervention group was significantly better than that of the simple treatment group, the 3- and 5-year survival rates were significantly higher than that of the simple treatment group, and the serum levels of GPC3 and LTBP2 as well as the incidence of adverse reactions were significantly lower than those of the simple treatment group (P < 0.05).

  Conclusion  Sorafenib combined with TACE can effectively prolong the survival time of patients with middle and advanced liver cancer, and the incidence of adverse reactions is low.